Loading
Early Alzheimer's Disease / CT1812 · Phase 2 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 2 clinical trial registration for CT1812 in early Alzheimer's disease with an 18-month primary outcome assessment using the CDR-SB scale. No results have been posted to the registry, so no efficacy, safety, or tolerability data are available for evaluation.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Early Alzheimer's Disease; age from 50 Years; to 85 Years. Intervention: CT1812 100 mg; CT1812 200 mg. Compared with: Placebo — Placebo Comparator. n = 540. 50 sites: United States.
This is a planned Phase 2 clinical trial registration for CT1812 in early Alzheimer's disease with an 18-month primary outcome assessment using the CDR-SB scale. No results have been posted to the registry, so no efficacy, safety, or tolerability data are available for evaluation.
This is a registry record with no results reported; efficacy, safety, and tolerability outcomes are unknown. No interim analyses, subgroup outcomes, or safety signals are reported in this record.
Clinicians and researchers should monitor this trial for results. Until efficacy and safety data are published or posted, no clinical recommendations can be made regarding CT1812.
Phase 2 trial with cognitive endpoint in early Alzheimer's disease; results not yet reported in this registry record, so no efficacy or safety data can be evaluated.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should monitor this trial for results. Until efficacy and safety data are published or posted, no clinical recommendations can be made regarding CT1812.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05531656). This is a study registration, not published results. Lead sponsor: Cognition Therapeutics. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 540 participants (ESTIMATED). Conditions: Early Alzheimer's Disease. Interventions: DRUG: CT1812; DRUG: Placebo. Primary outcome measures: Change from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale. , 18 months. Brief summary: This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.